Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study

OBJECTIVE: To evaluate the efficacy and safety of taspoglutide (R1583/BIM51077), a human once-weekly glucagon-like peptide-1 analog, in patients with type 2 diabetes inadequately controlled with metformin. RESEARCH DESIGN AND METHODS: Type 2 diabetic (n = 306) patients who failed to obtain glycemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Nauck, Michael A., Ratner, Robert E., Kapitza, Christoph, Berria, Rachele, Boldrin, Mark, Balena, Raffaella
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2009
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699710/
https://www.ncbi.nlm.nih.gov/pubmed/19366970
http://dx.doi.org/10.2337/dc08-1961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699710/
https://www.ncbi.nlm.nih.gov/pubmed/19366970
http://dx.doi.org/10.2337/dc08-1961

Ejemplares similares